Loading…
Loading…
WUHN does not currently pay a dividend.
See exactly how WUHN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for WUHN and 80,000+ other tickers.
Wuhan General Group (China), Inc. is a nutraceutical biotechnology company, which engages in the development of alternative plant-based cannabinoids and psilocybin medical research that commercializes a range of cannabidiol and mushrooms-based products under the Dr. AnnaRx, Medspresso and Handcrafted Delights brands. The firm is also engages in research and development of indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer's and Parkinson's. The company was founded by Xu Jie and Jeff Robinson on July 19, 1988 and is headquartered in Cape Town, South Africa.
Xometry (NASDAQ: XMTR - Get Free Report) and Wuhan General Group (OTCMKTS:WUHN - Get Free Report) are both industrials companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings. Insider and Institutional Ownership 97.3% of Xometry shares
Wuhan General Group (OTCMKTS:WUHN - Get Free Report) and Middleby (NASDAQ: MIDD - Get Free Report) are both industrials companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership. Analyst Ratings This is a summary of current
Wuhan General Group (OTCMKTS:WUHN - Get Free Report) and Standex International (NYSE: SXI - Get Free Report) are both industrials companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends. Analyst Ratings This is a summary of
CAPE TOWN, SA / ACCESSWIRE / September 23, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update: Newly appointed Chief Innovation Officer of M2Bio Sciences, Dr. Riyad Domingo , will present his inaugural webinar on the future of mental health therapeutics derived from the psychedelic prodrug psilocybin.
CAPE TOWN, SA / ACCESSWIRE / September 17, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research, is pleased to announce the following corporate update: M2Bio Sciences Food and Beverage is thrilled to launch the Medspresso CBD Infused Organic Whole Bean and Ground Coffee Range.